Jefferies Raises Price Target on WAVE Life Sciences (WVE) From $28 to $42

November 14, 2016 8:46 AM EST
Get Alerts WVE Hot Sheet
Price: $34.30 -7.3%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 31 | New: 25
Trade WVE Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Jefferies reiterated a Buy rating on WAVE Life Sciences (NASDAQ: WVE), and raised the price target to $42.00 (from $28.00), after meeting with management. WVE is making progress on two lead programs in Huntington’s disease (HD) & Duchenne Muscular Dystrophy (DMD), with both scheduled to enter clinic in 2017.

Analyst Eun Yang commented, "We attribute recent WVE share appreciation to: (1) progress in its pipeline candidates; (2) visibility from two recent KOL events on its core programs; (3) benefit from Exondys 51 approval; & (4) biotech rally post-election. While clinical utility of its candidates remains to be seen, on its timely execution to date & ability to continue to generate potentially best-in-class RNA therapies, we're increasing PT & maintaining Buy."

For an analyst ratings summary and ratings history on WAVE Life Sciences click here. For more ratings news on WAVE Life Sciences click here.

Shares of WAVE Life Sciences closed at $36.50 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment